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ABSTRACT 
Alfuzosin belongs to a class of drugs known as alpha blockers. As an antagonist of the alpha 1 adrenergic receptor, it works by relaxing the muscles in the 
prostate and bladder neck, making it easier to urinate. Alfuzosin gastro resistant prolonged release tablet was prepared as the prepared tablet will 
improve the bioavailability as well dosing frequency. The prepared gastro resistant prolonged release tablet was evaluated using HPLC. The release 
profile of each film coated prolonged release tablet contains Alfuzosin HCl IP. 10 mg was found to be range from 23.27 % to 93.58 % from 1st hour 
to 20th Hour of the release time. From the above study it was concluded that the prolonged release tablet of alfuzosin was found to be effective for long 
term therapy. 
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INTRODUCTION 
Pharmaceutical invention and research are increasingly 
focusing on delivery systems which enhance desirable 
therapeutic objectives while minimizing side effects. Oral 
drug delivery system represents one of the frontier areas of 
controlled drug delivery system. Such a dosage forms having 
a major advantage of patient compliance. Sustained or 
prolonged release dosage forms are designed to release a 
drug at a predetermined rate in order to maintain a constant 
drug concentration for a specific period of time with 
minimum side effects. Now days as very few drugs are 
coming out of research and development and already 
existing drugs are suffering the problem of resistance due to 
their irrational use specifically in case of drugs like 
antibiotics.1,2 Alfuzosin is freely soluble in water3, and thus 
readily absorbed after administration. The absorption is 
significantly aided by the presence of food. The dose of 
immediate release alfuzosin tablet is 2.5mg thrice daily, 
elimination half life is 3-5 hr and pka is 8.1.4 Recently 10 mg 
once daily extended release formulation has become 
available in the market5 which is more convenient for older 
patients. Marketed alfuzosin formulation is a three layered 
Geo matrix tablet that requires special facilities, high cost, 
time consuming and complex operation than conventional 
formulations. 6 The objective of development activities was 
to develop pharmaceutically equivalent, stable, cost effective, 
quality improved and robust formulation of Alfuzosin tablets 
10mg.Hence, change in the operation is a suitable and 
optimized way to make the some drug more effective by 
slight alteration in the drug delivery. Sustained or prolonged 
Release is also providing promising way to decrease the side 
effect of drug by preventing the fluctuation of the therapeutic 
concentration of the drug in the body. 7 
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MATERIALS & METHODS 
Table 1: Formulation for uncoated tablets 
Sr. 
No. 
Ingredients (Grade) Standard Quantity per tablet in mg 
Formulation F1  F2 F3 F4 F5 F6 
Intragranular  
1 Alfuzosin Hydrochloride* (IP) 10.00 10.00 10.00 10.00 10.00 10.00 
2 Microcrystalline cellulose Powder** (USP/BP) 153.10 135.10 65.10 81.10 56.10 54.10 
3 Hydroxypropylmethylcellulose K-100M (USP/BP) 20.00 34.00 34.00 22.00 45.00 35.00 
Binder 
4 PVP K 30 (USP/BP) 6.000 6.000 6.000 6.000 6.000 6.000 
5 Iso Propyl Alcohol (IPA)# USP/BP q. s. q. s. q. s. q. s. q. s. q. s. 
Lubrication 
6 Hydroxypropylmethylcellulose K-100 M (USP/BP) 6.00 6.00 10.00 6.00 8.00 20.00 
7 Aerosil (Colloidal silicon dioxide) (USP/BP) 0.400 0.400 0.400 0.400 0.400 0.400 
8 Purified Talcum (USP/BP) 1.500 1.500 1.500 1.500 1.500 1.500 
9 Magnesium Stearate (USP/BP) 3.000 3.000 3.000 3.000 3.000 3.000 
Average Total weight 200.0 200.0 135.0 130.0 133.0 130.0 
 
Table 2: Formulation for uncoated tablets 
Sr. No. Ingredients (Grade) Standard Quantity per tablet in mg 
Intragranular  
1 Alfuzosin Hydrochloride* (IP) 10.00 10.00 10.00 
2 Microcrystalline cellulose Powder** (USP/BP) 54.10 48.10 58.10 
3 Hydroxypropylmethylcellulose K-100M (USP/BP) 35.00 35.00 30.00 
Binder   
4 PVP K 30 (USP/BP) 6.000 12.000 12.000 
5 Iso Propyl Alcohol (IPA)# (USP/BP) q. s. q. s. q. s. 
Lubrication   
6 Hydroxypropylmethylcellulose K-100 M (USP/BP) 20.00 20.00 15.00 
7 Aerosil (Colloidal silicon dioxide ) (USP/BP) 0.400 0.400 0.400 
8 Purified Talcum (USP/BP) 1.500 1.500 1.500 
9 Magnesium Stearate (USP/BP) 3.000 3.000 3.000 
Average Total weight 130.0 130.0 130.0 
Film Coating  
 
  
10 Hydroxy propyl methyl cellulose (HPMC E-15) (USP/BP) 1.900 1.900 1.900 
11 PEG 6000 (USP/BP) 0.400 0.400 0.400 
12 Colour Titanium Dioxide (IP) 0.500 0.500 0.500 
13  Purified Talcum  (USP/BP) 0.200 0.200 0.200 
14 Isopropyl alcohol (IPA)# (USP/BP) q.s. q.s. q.s. 
15 Dichloro methane (MDC)# (USP/BP) q.s. q.s. q.s. 
Average Total weight of coated  tablet 
 
133.00 133.00 133.00 
 
Remarks: 
*API quantity calculated as per Minimum Assay & Maximum Water   
**Actual quantity of API after assay & LOD calculation to be compensated using microcrystalline cellulose Powder as filler. 
# does not appear in the final product.  
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Manufacturing of Tablet: 8,9 
 
Figure 1: Flow Chart of manufacturing process of Alfuzosin tablets 
 
RESULT & DISCUSSION 
S. No. Parameters Specifications Results 
1.  Description White colored round shaped 
biconvex film coated tablet 
plain on both sides. 
White colored round shaped biconvex 
film coated tablet plain on both sides. 
2.  Identification of Alfuzosin (By HPLC) 
 
In the assay, the retention time 
of principle peak of Alfuzosin 
obtained in chromatogram of 
test solution corresponds to 
the chromatogram obtained 
with the Standard Solution. 
In the assay, the retention time of 
principle peak of Alfuzosin obtained in 
chromatogram of test solution 
corresponds to the chromatogram 
obtained with the Standard Solution. 
3.  Average Weight 133 mg + 5% 126.8 mg 
4.  Uniformity of  Weight Average weight + 5.0% Complies 
5.  Dissolution  (By HPLC) 
Each film coated prolonged release 
tablet contains: 
Alfuzosin HCl IP.........10 mg 
eq. to Alfuzosin 
1st Hour 
 
6th Hour 
 
20t Hour 
 
 
 
 
NMT 35 % 
 
 
Between 30 % to 75 % 
NLT 80 % 
 
 
 
 
Min : 20.98 % Max : 25.57 % 
Avg : 23.27 % 
Min :59.76 %  Max : 69.68 % 
Avg : 64.72 % 
Min :93.34 %  Max : 94.64 % 
Avg : 93.58 % 
6.  Assay (By HPLC) 
Each film coated prolonged release 
tablet contains: 
Alfuzosin HCl IP.........10 mg 
eq. to Alfuzosin 
 
95 % to 105 % 
 
% (  mg/ Tab) 
7.  Additional Tests 
Diameter 
Thickness 
7.00 mm +  0.2 mm 
3.40 mm +  0.2 mm 
 
7.12  mm 
3. 48 mm 
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Dissolution Release Profile 
 
Result 20 hours  
Reference       Trial 
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CONCLUSION 
There are number of drugs are formulated now in a variety 
of different per oral extended-release dosage forms. 
However, only those that will result in a significant reduction 
in dose frequency and/or a reduction in toxicity resulting 
from high concentration in the blood or gastrointestinal tract 
are likely to improve therapeutic outcomes. To formulate a 
successful extended-release product, the drug must be 
released from the dosage form at a predetermined rate, 
dissolve in the gastrointestinal fluids, maintain sufficient 
gastrointestinal residence time, and may be absorbed at a 
rate and will replace the amount of drug being metabolized 
and excreted. The oral extended or prolonged release 
formulations must have the following properties. They 
exhibit neither very slow nor very fast rates of absorption 
and excretion. They are uniformly absorbed from the 
gastrointestinal tract. They are administered in relatively 
small doses. They possess a good margin of study and they 
are used in the treatment of chronic rather than acute 
conditions.  
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